Coya Therapeutics (COYA) Free Cash Flow (2022 - 2026)

Coya Therapeutics (COYA) has 5 years of Free Cash Flow data on file, last reported at -$6.2 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 119.52% year-over-year to -$6.2 million; the trailing twelve-month figure through Mar 2026 stood at -$14.1 million (up 7.49% YoY), and the FY2025 full-year result was -$10.7 million, down 4.38% from the prior year.
• Free Cash Flow declined to -$6.2 million in Q1 2026, from -$1.0 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $2.1 million in Q1 2024 to a low of -$6.2 million in Q1 2026.
• A 5-year average of -$2.7 million and a median of -$2.2 million in 2023 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow surged 155.54% in 2024 and plunged 231.8% in 2025, its largest moves.
• Tracing COYA's Free Cash Flow over 5 years: stood at -$2.2 million in 2022, then declined by 0.81% to -$2.2 million in 2023, then slipped by 7.53% to -$2.4 million in 2024, then surged by 58.21% to -$1.0 million in 2025, then slumped by 516.46% to -$6.2 million in 2026.
• Business Quant data shows COYA's Free Cash Flow at -$6.2 million in Q1 2026, -$1.0 million in Q4 2025, and -$1.1 million in Q3 2025.